Suppr超能文献

心肌梗死后患者的利多卡因和吲哚菁绿动力学

Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

作者信息

Bax N D, Tucker G T, Woods H F

出版信息

Br J Clin Pharmacol. 1980 Oct;10(4):353-61. doi: 10.1111/j.1365-2125.1980.tb01771.x.

Abstract
  1. Blood clearances of lignocaine and indocyanine green together with indocyanine green half-lives were measured in 17 post-myocardial infarct patients (one patient was studied twice) between 8 h and 36 h after starting intravenous lignocaine infusions for the treatment of cardiac arrhythmias. 2. Mean +/- s.d. values of lignocaine clearance (ml min-1 kg-1) were higher in patients without heart failure (11.8 +/- 2.6, n = 9) than in those with heart failure (7.2 +/- 1.9, n = 9) (P < 0002). 3. Clearances of lignocaine and indocyanine green were not correlated but lignocaine clearance was directly related to the reciprocal of indocyanine green half-life (rs = 0.67, P < 0.01). 4. In eight patients who received both lignocaine and indocyanine green and in a further five patients received only lignocaine and whose lignocaine infusions lasted 24h or more, a 25% rise in lignocaine concentrations was observed between 8-12h and 24-28h. 5. The mean +/- s.d. post-infusion terminal half-life of lignocaine in four patients whose lignocaine infusions lasted 30h or longer was 7.2 +/- 2.1 h. 6. Heart failure was associated with greater changes in lignocaine kinetics than in indocyanine green kinetics. 72% of the variance between observed and predicted lignocaine clearances could be accounted for by multiple linear regression analysis incorporating indocyanine green half-life and the presence or absence of heart failure. Indocyanine green half-life contributed only 17% of the variance indicating that by itself it is of limited value in predicting lignocaine requirements. 7. Lignocaine kinetics during and after prolonged intravenous infusion were not predicted by data obtained after intravenous bolus injection. 8. A lowering of lignocaine dosage may be clinically desirable in the presence of heart failure and if an infusion lasts longer than 24 h.
摘要
  1. 在17例心肌梗死后患者(1例患者接受了两次研究)中,于开始静脉输注利多卡因治疗心律失常后8小时至36小时期间,测定了利多卡因和吲哚菁绿的血液清除率以及吲哚菁绿的半衰期。2. 无心力衰竭患者的利多卡因清除率(毫升·分钟⁻¹·千克⁻¹)的均值±标准差(11.8±2.6,n = 9)高于有心力衰竭患者(7.2±1.9,n = 9)(P < 0.002)。3. 利多卡因和吲哚菁绿的清除率无相关性,但利多卡因清除率与吲哚菁绿半衰期的倒数直接相关(rs = 0.67,P < 0.01)。4. 在8例同时接受利多卡因和吲哚菁绿的患者以及另外5例仅接受利多卡因且利多卡因输注持续24小时或更长时间的患者中,观察到利多卡因浓度在8 - 12小时和24 - 28小时之间升高了25%。5. 4例利多卡因输注持续30小时或更长时间的患者,输注后利多卡因的平均±标准差终末半衰期为7.2±2.1小时。6. 心力衰竭与利多卡因动力学变化的关联大于与吲哚菁绿动力学变化的关联。通过纳入吲哚菁绿半衰期和心力衰竭的存在与否进行多元线性回归分析,可以解释观察到的和预测的利多卡因清除率之间72%的差异。吲哚菁绿半衰期仅占差异的17%,表明其自身在预测利多卡因需求量方面价值有限。7. 静脉推注注射后获得的数据无法预测长时间静脉输注期间及之后的利多卡因动力学。8. 在存在心力衰竭且输注持续超过24小时的情况下,临床上可能需要降低利多卡因剂量。

相似文献

1
Lignocaine and indocyanine green kinetics in patients following myocardial infarction.
Br J Clin Pharmacol. 1980 Oct;10(4):353-61. doi: 10.1111/j.1365-2125.1980.tb01771.x.
2
Lidocaine kinetics predicted by indocyanine green clearance.
N Engl J Med. 1978 May 25;298(21):1160-3. doi: 10.1056/NEJM197805252982102.
3
The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.
Br J Clin Pharmacol. 1985 May;19(5):597-603. doi: 10.1111/j.1365-2125.1985.tb02686.x.
4
Lidocaine kinetics: relationships between early lidocaine kinetics and indocyanine green clearance.
J Clin Pharmacol. 1981 Feb-Mar;21(2):100-5. doi: 10.1002/j.1552-4604.1981.tb01757.x.
5
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Br Med J. 1976 Apr 17;1(6015):939-41. doi: 10.1136/bmj.1.6015.939.
7
Clinical pharmacokinetics of lignocaine.
Clin Pharmacokinet. 1978 May-Jun;3(3):177-201. doi: 10.2165/00003088-197803030-00001.
9
Does indocyanine green predict lidocaine requirements?
N Engl J Med. 1978 Sep 21;299(12):662-3. doi: 10.1056/nejm197809212991215.
10
Protein binding and disposition of lignocaine in the elderly.
Eur J Clin Pharmacol. 1985;29(3):323-9. doi: 10.1007/BF00544089.

引用本文的文献

1
Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review.
Clin Pharmacokinet. 2024 May;63(5):623-643. doi: 10.1007/s40262-024-01373-4. Epub 2024 May 4.
2
Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats.
Mol Imaging Biol. 2010 Dec;12(6):583-94. doi: 10.1007/s11307-010-0317-x.
3
On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
Br J Clin Pharmacol. 1982 Mar;13(3):411-5. doi: 10.1111/j.1365-2125.1982.tb01394.x.
4
Time-dependent kinetics of lignocaine in the isolated perfused rat liver.
J Pharmacokinet Biopharm. 1983 Apr;11(2):165-82. doi: 10.1007/BF01061847.
5
Rapid prediction of individual dosage requirements for lignocaine.
Clin Pharmacokinet. 1984 Jul-Aug;9(4):354-63. doi: 10.2165/00003088-198409040-00005.
6
Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.
Clin Pharmacokinet. 1984 Jul-Aug;9(4):273-308. doi: 10.2165/00003088-198409040-00001.
7
Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):21S-28S. doi: 10.1111/j.1365-2125.1984.tb02424.x.
8
Lack of effect of ranitidine on the disposition of lignocaine.
Br J Clin Pharmacol. 1983 Mar;15(3):378-9. doi: 10.1111/j.1365-2125.1983.tb01514.x.
9
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility.
Br J Clin Pharmacol. 1981 Sep;12(3):429-31. doi: 10.1111/j.1365-2125.1981.tb01240.x.
10
Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers.
Br J Clin Pharmacol. 1987 Jun;23(6):693-701. doi: 10.1111/j.1365-2125.1987.tb03103.x.

本文引用的文献

3
Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.
Circulation. 1971 Feb;43(2):205-11. doi: 10.1161/01.cir.43.2.205.
4
Evaluation of lidocaine resistance in man using intermittent large-dose infusion techniques.
Am J Cardiol. 1974 Sep;34(3):342-9. doi: 10.1016/0002-9149(74)90037-x.
5
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
Ann Intern Med. 1973 Apr;78(4):499-508. doi: 10.7326/0003-4819-78-4-499.
8
GLC analysis of lidocaine in blood using an alkaline flame-ionization detector.
J Pharm Sci. 1976 Apr;65(4):608-10. doi: 10.1002/jps.2600650435.
9
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Br Med J. 1976 Apr 17;1(6015):939-41. doi: 10.1136/bmj.1.6015.939.
10
Logical approach to lignocaine therapy.
Br Med J. 1976 Jan 3;1(6000):13-5. doi: 10.1136/bmj.1.6000.13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验